Updated Results Of The Monaleesa-2 Trial In Hr+/Her2- Breast Cancer

Updated Results of the MONALEESA-2 Trial in HR+/HER2- Breast Cancer

Targeted Oncology

Dr. Burris on Updated MONALEESA-2 Trial Results for HR+ Breast Cancer

Dr. Hortobagyi on MONALEESA-2 Trial Results in Breast Cancer

MONALEESA-2: improved OS seen in HR+ advanced breast cancer treated with ribociclib + letrozole

Results of the MONALEESA-2 Study in Advanced Breast Cancer

Targeted Oncology

ESMO 2016: Press brief on the MONALEESA-2 clinical trial on breast cancer

MONALEESA-2: ribociclib + letrozole in pts with de novo metastatic disease and late recurrence

QOL in MONALEESA-2, 3, and 7

Overall survival results from MONALEESA-2: Endocrine therapy and ribociclib in HR positive and H...

Dr. Gabriel Hortobagyi on the Impact of MONALEESA-2 Trial in HR+ Breast Cancer

Dr. Slamon the Phase III Results of MONALEESA-3 Trial in HR+/HER2- Breast Cancer

Safety and efficacy of ribociclib and letrozole in advanced breast cancer – the MONALEESA-2 trial

Overall Survival Data of the MONARCH-2 Trial in HR+/HER2- Breast Cancer

Targeted Oncology

MONALEESA-3 OS results: fulvestrant/ribociclib in postmenopausal HR+/HER2- advanced breast cancer

Dr. Slamon on OS Results of the MONALEESA-3 Trial in HR+/HER2- Breast Cancer

Practical Implications of the MONALEESA-3 Trial

Targeted Oncology

Dr. Varella on the Results of MONALEESA-7 in HR+/HER2- Breast Cancer

Overall survival results from MONALEESA-3 study on ribociclib plus fulvestrant in advanced breas...

ADAPT trial: Endocrine + ribociclib vs. chemotherapy in HR+/HER2- early breast cancer

Key trial updates in SERDs in ER+/HER2- breast cancer from SABCs 2022